SHANGHAI, May 6, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced the completion of patient enrollment in the global Phase III pivotal multi-regional clinical trial (RESPOND-2, Study AP301-HP-03) of AP301, a novel fiber-iron-based phosphate binder, for the treatment of hyperphosphatemia. The trial was conducted in the United States and China, led by Dr. Geoffrey A. Block of U.S. Renal Care, with Professor Xiaoqiang Ding, Director of the Department of Nephrology, Zhongshan Hospital, Fudan University serving as the China principal investigator, and enrolled a total of 282 chronic kidney disease ("CKD") patients on maintenance dialysis with hyperphosphatemia — 138 in the U.S. and 144 in China.

As a next-generation fiber-iron-based phosphate binder, AP301 is designed to have a higher phosphate-binding capability, favorable gastrointestinal tolerability, minimal risk of iron overload, and no requirement for chewing before swallowing, with the potential to improve treatment adherence and effectively control hyperphosphatemia.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.